Systemic Therapy for Colon Cancer

被引：125
作者：
Wu, Christina [1 ]
机构：
[1] Winship Canc Inst, Dept Hematol Oncol, 1365-C Clifton Rd Northeast, Atlanta, GA 30322 USA
来源：
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA | 2018年 / 27卷 / 02期
关键词：
Irinotecan; Oxaliplatin; 5-fluorouracil; Antiepidermal growth factor receptor antibody; Vascular endothelial growth factor antibody; Immunotherapy; Regorafenib; Trifluridine/tipiracil; ADVANCED COLORECTAL-CANCER; SUBGROUP ANALYSES; ADJUVANT THERAPY; STAGE-II; MISMATCH-REPAIR; FLUOROURACIL; LEUCOVORIN; OXALIPLATIN; CHEMOTHERAPY; IRINOTECAN;
D O I：
10.1016/j.soc.2017.11.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Systemic treatments for patients with colon cancer has expanded broadly beyond 5-fluorouracil-based chemotherapy. For patients with early-stage colon cancer who are considering adjuvant chemotherapy, multiple factors such as the risk of disease recurrence, absolute survival benefit of chemotherapy, treatment toxicity, and patient comorbid medical conditions must be taken into account. In the metastatic setting, biomarkers such as KRAS/NRAS/BRAF mutation, microsatellite instability status, and left- versus right-sided colon cancer have helped oncologists to tailor systemic treatment regimens, which include chemotherapy, targeted therapy, and immunotherapy.
引用
收藏
页码：235 / +
页数：9
相关论文
共 22 条
  • [11] Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial
    Koopman, Miriam
    Antonini, Ninja F.
    Douma, Joep
    Wals, Jaap
    Honkoop, Aafke H.
    Erdkamp, Frans L. G.
    de Jong, Robert S.
    Rodenburg, Cees J.
    Vreugdenhil, Gerard
    Loosveld, Olaf J. L.
    van Bochove, Aart
    Sinnige, Harm A. M.
    Creemers, Geert-Jan M.
    Tesselaar, Margot E. T.
    Slee, Peter H. Th J.
    Werter, Marjon J. B. P.
    Mol, Linda
    Dalesio, Otilia
    Punt, Cornelis J. A.
    [J]. LANCET, 2007, 370 (9582) : 135 - 142
  • [12] PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
    Le, D. T.
    Uram, J. N.
    Wang, H.
    Bartlett, B. R.
    Kemberling, H.
    Eyring, A. D.
    Skora, A. D.
    Luber, B. S.
    Azad, N. S.
    Laheru, D.
    Biedrzycki, B.
    Donehower, R. C.
    Zaheer, A.
    Fisher, G. A.
    Crocenzi, T. S.
    Lee, J. J.
    Duffy, S. M.
    Goldberg, R. M.
    de la Chapelle, A.
    Koshiji, M.
    Bhaijee, F.
    Huebner, T.
    Hruban, R. H.
    Wood, L. D.
    Cuka, N.
    Pardoll, D. M.
    Papadopoulos, N.
    Kinzler, K. W.
    Zhou, S.
    Cornish, T. C.
    Taube, J. M.
    Anders, R. A.
    Eshleman, J. R.
    Vogelstein, B.
    Diaz, L. A., Jr.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (26) : 2509 - 2520
  • [13] Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
    Le, Dung T.
    Durham, Jennifer N.
    Smith, Kellie N.
    Wang, Hao
    Bartlett, Bjarne R.
    Aulakh, Laveet K.
    Lu, Steve
    Kemberling, Holly
    Wilt, Cara
    Luber, Brandon S.
    Wong, Fay
    Azad, Nilofer S.
    Rucki, Agnieszka A.
    Laheru, Dan
    Donehower, Ross
    Zaheer, Atif
    Fisher, George A.
    Crocenzi, Todd S.
    Lee, James J.
    Greten, Tim F.
    Duffy, Austin G.
    Ciombor, Kristen K.
    Eyring, Aleksandra D.
    Lam, Bao H.
    Joe, Andrew
    Kang, S. Peter
    Holdhoff, Matthias
    Danilova, Ludmila
    Cope, Leslie
    Meyer, Christian
    Zhou, Shibin
    Goldberg, Richard M.
    Armstrong, Deborah K.
    Bever, Katherine M.
    Fader, Amanda N.
    Taube, Janis
    Housseau, Franck
    Spetzler, David
    Xiao, Nianqing
    Pardoll, Drew M.
    Papadopoulos, Nickolas
    Kinzler, Kenneth W.
    Eshleman, James R.
    Vogelstein, Bert
    Anders, Robert A.
    Diaz, Luis A., Jr.
    [J]. SCIENCE, 2017, 357 (6349) : 409 - 413
  • [14] Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
    Mayer, Robert J.
    Van Cutsem, Eric
    Falcone, Alfredo
    Yoshino, Takayuki
    Garcia-Carbonero, Rocio
    Mizunuma, Nobuyuki
    Yamazaki, Kentaro
    Shimada, Yasuhiro
    Tabernero, Josep
    Komatsu, Yoshito
    Sobrero, Alberto
    Boucher, Eveline
    Peeters, Marc
    Tran, Ben
    Lenz, Heinz-Josef
    Zaniboni, Alberto
    Hochster, Howard
    Cleary, James M.
    Prenen, Hans
    Benedetti, Fabio
    Mizuguchi, Hirokazu
    Makris, Lukas
    Ito, Masanobu
    Ohtsu, Atsushi
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (20) : 1909 - 1919
  • [15] PIEDBOIS P, 1992, J CLIN ONCOL, V10, P896
  • [16] Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
    Sargent, Daniel J.
    Marsoni, Silvia
    Monges, Genevieve
    Thibodeau, Stephen N.
    Labianca, Roberto
    Hamilton, Stanley R.
    French, Amy J.
    Kabat, Brian
    Foster, Nathan R.
    Torri, Valter
    Ribic, Christine
    Grothey, Axel
    Moore, Malcolm
    Zaniboni, Alberto
    Seitz, Jean-Francois
    Sinicrope, Frank
    Gallinger, Steven
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) : 3219 - 3226
  • [17] Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX plus /- cetuximab chemotherapy: NCCTG N0147 (Alliance).
    Sinicrope, Frank A.
    Shi, Qian
    Smyrk, Thomas C.
    Goldberg, Richard M.
    Heying, Erica N.
    Cohen, Steven J.
    Gill, Sharlene
    Kahlenberg, Morton S.
    Nair, Suresh
    Shields, Anthony Frank
    Sargent, Daniel J.
    Jahagirdar, Balkrishna N.
    Pollak, Michael N.
    Alberts, Steven R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [18] DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
    Sinicrope, Frank A.
    Foster, Nathan R.
    Thibodeau, Stephen N.
    Marsoni, Silvia
    Monges, Genevieve
    Labianca, Roberto
    Yothers, Greg
    Allegra, Carmen
    Moore, Malcolm J.
    Gallinger, Steven
    Sargent, Daniel J.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (11): : 863 - 875
  • [19] Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial
    Tabernero, Josep
    Van Cutsem, Eric
    Lakomy, Radek
    Prausova, Jana
    Ruff, Paul
    van Hazel, Guy A.
    Moiseyenko, Vladimir M.
    Ferry, David R.
    McKendrick, Joseph J.
    Soussan-Lazard, Karen
    Chevalier, Soazig
    Allegra, Carmen J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (02) : 320 - 331
  • [20] FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:: A randomized GERCOR study
    Tournigand, C
    André, T
    Achille, E
    Lledo, G
    Flesh, M
    Mery-Mignard, D
    Quinaux, E
    Couteau, C
    Buyse, M
    Ganem, G
    Landi, B
    Colin, P
    Louvet, C
    de Gramont, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (02) : 229 - 237
123